RPL26: A Potential Drug Target for Neurodegenerative Diseases

Target Name: RPL26

NCBI ID: G6154

RPL26

RPL26: A Potential Drug Target for Neurodegenerative Diseases

RPL26 (OTTHUMP00000135333) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the P-type Ca2+ ATPase family, which is a family of transmembrane proteins that are involved in the regulation of intracellular calcium levels. P-type Ca2+ ATPases are known for their ability to ATPize, which means they generate ATP through the process of phosphorylation of the protein's catalytic active site. This process allows the P-type Ca2+ ATPases to regulate the levels of intracellular calcium ions, which are essential for various physiological processes, including muscle contractions, nerve function, and cell signaling.

The P-type Ca2+ ATPase family has been identified as a potential drug target in the field of neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease. These diseases are characterized by the progressive loss of brain cells and the development of debilitating symptoms. The P-type Ca2+ ATPases are thought to play a role in the development and progression of these diseases, as they are involved in the regulation of the levels of intracellular calcium ions.

In addition to its potential as a drug target, RPL26 is also a biomarker for several diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. The presence of RPL26 in the brains of individuals with these diseases has been confirmed using various techniques, such as Western blotting and immunofluorescence.

The Role of RPL26 in Cell signaling

RPL26 is involved in the regulation of intracellular calcium ions through its P-type Ca2+ ATPase activity. This protein is known for its ability to regulate the levels of intracellular calcium ions in a variety of cell types, including neurons and muscle cells.

In neurons, RPL26 is involved in the regulation of the intracellular calcium ion levels that are required for the regulation of neuronal excitability. This is done through the regulation of the amount of neurotransmitter release that occurs from the neuron, as well as the regulation of the intracellular calcium ion levels.

In muscle cells, RPL26 is involved in the regulation of the intracellular calcium ion levels that are required for muscle contractions. This is done through the regulation of the amount of calcium ion channels that are open in muscle cells, as well as the regulation of the intracellular calcium ion levels.

The Effects of RPL26 on Cell signaling

The effects of RPL26 on cell signaling are complex and involve the regulation of a variety of intracellular biological processes. In neurons, RPL26 is involved in the regulation of neurotransmitter release, which is critical for the regulation of neuronal excitability.

In muscle cells, RPL26 is involved in the regulation of muscle contractions. This is done through the regulation of the amount of calcium ion channels that are open in muscle cells, as well as the regulation of the intracellular calcium ion levels.

The regulation of intracellular calcium ions by RPL26 is critical for the function of many cellular processes, including neuronal signaling, muscle contractions, and blood vessel regulation. It is also thought to be involved in the development and progression of several neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.

Potential Therapeutic Applications

The potential therapeutic applications for RPL26 are vast, as it is involved in the regulation of many cellular processes that are important for human health. The regulation of intracellular calcium ions by RPL26 is a potential therapeutic target for

Protein Name: Ribosomal Protein L26

Functions: Component of the large ribosomal subunit (PubMed:26100019, PubMed:23636399, PubMed:32669547). The ribosome is a large ribonucleoprotein complex responsible for the synthesis of proteins in the cell (PubMed:26100019, PubMed:23636399, PubMed:32669547)

The "RPL26 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPL26 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets